You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuinidine
Accession NumberDB00908  (APRD00136)
TypeSmall Molecule
GroupsApproved
DescriptionAn optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. [PubChem]
Structure
Thumb
Synonyms
(+)-quinidine
(8R,9S)-Quinidine
(R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol
(S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol
(S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol
6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol
alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol
beta-Quinine
Chinidin
Chinidinum
CIN-QUIN
Conchinin
Conquinine
Kinidin
Pitayine
Quinidina
Quinidine
β-quinine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cardioquin Tabletstablet275 mgoralPurdue Pharma1961-12-312000-07-17Canada
Novo-quinidin 200mgtablet200 mgoralNovopharm Limited1966-12-312005-08-10Canada
Quinate Tab 325mgtablet325 mgoralRougier Pharma Division Of Ratiopharm Inc1979-12-312003-09-22Canada
Quinidex Extentabs Srt 300mgtablet (extended-release)300 mgoralAyerst Laboratories1991-12-311996-09-10Canada
Quinidex Extentabs Srt 300mgtablet (extended-release)300 mgoralWyeth Ayerst Canada Inc.1994-12-312001-10-29Canada
Quinidine 200 Tabtablet200 mgoralPro Doc Limitee1982-12-312003-07-31Canada
Quinidine Gluconatesolution80 mg/mLintravenousEli Lilly and Company1951-03-01Not applicableUs
Quinidine Gluconate for Inj 80mg/ml USPliquid80 mgintramuscular; intravenousEli Lilly Canada Inc1991-12-311997-08-13Canada
Quinidine Sulfate 200mgtablet200 mgoralRougier Pharma Division Of Ratiopharm Inc1970-12-311999-09-27Canada
Quinidine Sulfate Injection 190mg/mlsolution190 mgintramuscularHospira Healthcare Corporation1981-12-31Not applicableCanada
Quinidine Sulfate Tab 200mgtablet200 mgoralGlaxo Wellcome Inc.1938-12-311999-08-24Canada
Quinidine Sulfate Tab 200mgtablet195 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1957-12-312001-07-20Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Quinidine Tab 200mgtablet200 mgoralApotex Inc1979-12-312010-01-19Canada
Apo-quin-G Tab 325mgtablet325 mgoralApotex Inc1985-12-312010-01-19Canada
Quinidine Gluconatetablet, extended release324 mg/1oralCarilion Materials Management1987-02-10Not applicableUs
Quinidine Gluconatetablet, extended release324 mg/1oralMutual Pharmaceutical Company, Inc.1987-02-10Not applicableUs
Quinidine Gluconatetablet, extended release324 mg/1oralRichmond Pharmaceuticals, Inc.1987-02-10Not applicableUs
Quinidine Sulfatetablet300 mg/1oralEon Labs, Inc.1983-09-26Not applicableUs
Quinidine Sulfatetablet200 mg/1oralEon Labs, Inc.1976-11-24Not applicableUs
Quinidine Sulfatetablet200 mg/1oralWatson Laboratories, Inc.1976-11-24Not applicableUs
Quinidine Sulfatetablet200 mg/1oralCarilion Materials Management1976-11-24Not applicableUs
Quinidine Sulfatetablet, film coated, extended release300 mg/1oralTeva Pharmaceuticals USA Inc1995-01-012016-03-31Us
Quinidine Sulfatetablet300 mg/1oralWatson Laboratories, Inc.1981-06-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CardioquinNot Available
KinidinNot Available
Quin-ReleaseNot Available
QuinagluteNot Available
QuinalanNot Available
QuinicardineNot Available
QuinidexNot Available
Brand mixtures
NameLabellerIngredients
NuedextaAvanir Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Quinidine gluconate
ThumbNot applicableDBSALT001251
Quinidine polygalacturonate
ThumbNot applicableDBSALT001344
Quinidine sulfate
Thumb
  • InChI Key: LOUPRKONTZGTKE-UYVJDWJCSA-N
  • Monoisotopic Mass: 324.183778022
  • Average Mass: 324.4168
DBSALT000363
Categories
UNIIITX08688JL
CAS number56-54-2
WeightAverage: 324.4168
Monoisotopic: 324.183778022
Chemical FormulaC20H24N2O2
InChI KeyInChIKey=LOUPRKONTZGTKE-LHHVKLHASA-N
InChI
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
IUPAC Name
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
SMILES
[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cinchona alkaloids. These are alkaloids structurally characterized by the presence of the cinchonan skeleton, which consists of a quinoline linked to an azabicyclo[2.2.2]octane moiety.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassCinchona alkaloids
Sub ClassNot Available
Direct ParentCinchona alkaloids
Alternative Parents
Substituents
  • Cinchonan-skeleton
  • Hydroxyquinoline
  • Quinoline
  • Quinuclidine
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Piperidine
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of ventricular pre-excitation and cardiac dysrhythmias
PharmacodynamicsQuinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.
Mechanism of actionQuinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Quinidine may also act on the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 2 to 3 L/kg
  • 0.5 L/kg [congestive heart failure]
  • 3 to 5 L/kg [cirrhosis of the liver]
Protein binding80-88%
Metabolism
SubstrateEnzymesProduct
Quinidine
3-HydroxyquinidineDetails
Route of eliminationWhen the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline.
Half life6-8 hours
Clearance
  • 3 – 5 mL/min/kg [adults]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Quinidine Action PathwayDrug actionSMP00323
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9836
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8208
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.762
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7225
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.972
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0596 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5884
hERG inhibition (predictor II)Inhibitor0.538
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Warner chilcott div warner lambert co
  • Bayer healthcare pharmaceuticals inc
  • Lannett co inc
  • Watson laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Halsey drug co inc
  • Mutual pharmaceutical co inc
  • Roxane laboratories inc
  • Sandoz inc
  • Superpharm corp
  • Pharmaceutical research assoc inc
  • Solvay pharmaceuticals
  • Wyeth pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Barr laboratories inc
  • Clonmel healthcare ltd
  • Contract pharmacal corp
  • Elkins sinn div ah robins co inc
  • Everylife
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • King pharmaceuticals inc
  • Kv pharmaceutical co
  • Lederle laboratories div american cyanamid co
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Scherer laboratories inc
  • Usl pharma inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Key pharmaceuticals inc sub schering plough corp
  • Schering corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral275 mg
Capsule, gelatin coatedoral
Tabletoral325 mg
Tablet (extended-release)oral300 mg
Solutionintravenous80 mg/mL
Tablet, extended releaseoral324 mg/1
Liquidintramuscular; intravenous80 mg
Tabletoral200 mg/1
Tabletoral300 mg/1
Tablet, film coated, extended releaseoral300 mg/1
Solutionintramuscular190 mg
Tabletoral195 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Quinidine gluc 80 mg/ml vial2.16USD ml
Quinidine sulfate crystals1.58USD g
QuiNIDine Gluconate CR 324 mg Controlled Release Tabs0.97USD tab
Quinidine gluc er 324 mg tab0.93USD each
Quinidine Sulfate 300 mg0.41USD tablet
Quinidine sulfate 300 mg tablet0.4USD tablet
Quinidine Sulfate 200 mg0.22USD tablet
Quinidine sulfate 200 mg tablet0.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7659282 No2006-08-132026-08-13Us
US8227484 No2003-07-172023-07-17Us
USRE38115 No1996-01-262016-01-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174 °CPhysProp
water solubility140 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.44HANSCH,C ET AL. (1995)
logS-3.37ADME Research, USCD
Caco2 permeability-4.69ADME Research, USCD
pKa8.56 (at 25 °C)SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.334 mg/mLALOGPS
logP2.82ALOGPS
logP2.51ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)9.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.59 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.69 m3·mol-1ChemAxon
Polarizability35.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (2.96 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jean Paul REMON, Chris Vervaet, “QUININE AND QUINIDINE SALTS, METHODS FOR MAKING THEM, AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM.” U.S. Patent US20090239900, issued September 24, 2009.

US20090239900
General ReferencesNot Available
External Links
ATC CodesC01BA01C01BA51C01BA71
AHFS Codes
  • 24:04.04.04
PDB EntriesNot Available
FDA labelDownload (615 KB)
MSDSDownload (73 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Quinidine can be decreased when used in combination with 1,10-Phenanthroline.
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Quinidine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Quinidine can be decreased when combined with 2-mercaptobenzothiazole.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Quinidine.
AbirateroneThe serum concentration of Quinidine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Quinidine.
AcenocoumarolQuinidine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Quinidine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Quinidine.
AcetazolamideAcetazolamide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Quinidine.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Quinidine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Quinidine.
AclidiniumAclidinium may increase the anticholinergic activities of Quinidine.
AclidiniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Aclidinium.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Quinidine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Quinidine.
AlbendazoleThe serum concentration of Quinidine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Quinidine can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Quinidine.
AlectinibThe serum concentration of Quinidine can be increased when it is combined with Alectinib.
AlfentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Alfentanil.
AlfentanilThe serum concentration of Quinidine can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Quinidine.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Quinidine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Quinidine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Quinidine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Quinidine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Quinidine is combined with Alphacetylmethadol.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Quinidine.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
AmantadineThe serum concentration of Quinidine can be increased when it is combined with Amantadine.
AmbenoniumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Ambenonium.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Quinidine.
AmilorideThe therapeutic efficacy of Quinidine can be decreased when used in combination with Amiloride.
AmineptineAmineptine may increase the QTc-prolonging activities of Quinidine.
Aminohippuric acidThe serum concentration of Quinidine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Quinidine.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Quinidine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quinidine.
AmlodipineThe serum concentration of Quinidine can be increased when it is combined with Amlodipine.
AmorolfineThe metabolism of Quinidine can be decreased when combined with Amorolfine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Quinidine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Quinidine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Quinidine.
Amphotericin BThe metabolism of Quinidine can be decreased when combined with Amphotericin B.
AmprenavirThe serum concentration of Quinidine can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Quinidine.
AmsacrineThe serum concentration of Quinidine can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Quinidine.
AN2690The metabolism of Quinidine can be decreased when combined with AN2690.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Quinidine.
AnidulafunginThe metabolism of Quinidine can be decreased when combined with Anidulafungin.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Quinidine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Quinidine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Quinidine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Quinidine.
AprepitantThe serum concentration of Quinidine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Quinidine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Quinidine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Quinidine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Quinidine.
Arsenic trioxideQuinidine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Quinidine can be decreased when combined with Artemether.
ArtemetherQuinidine may increase the QTc-prolonging activities of Artemether.
AsenapineQuinidine may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Quinidine can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Quinidine.
AtazanavirThe serum concentration of Quinidine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Quinidine.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Quinidine.
AtomoxetineThe metabolism of Quinidine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Quinidine can be increased when it is combined with Atorvastatin.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Quinidine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Quinidine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Quinidine.
AzelastineThe serum concentration of Quinidine can be increased when it is combined with Azelastine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Quinidine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Quinidine.
Bafilomycin A1The metabolism of Quinidine can be decreased when combined with Bafilomycin A1.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Quinidine.
BenactyzineThe risk or severity of adverse effects can be increased when Quinidine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Quinidine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Quinidine.
BenzocaineThe serum concentration of Quinidine can be increased when it is combined with Benzocaine.
Benzoic AcidThe metabolism of Quinidine can be decreased when combined with Benzoic Acid.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Quinidine.
BepridilThe serum concentration of Quinidine can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Quinidine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Quinidine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Quinidine.
BexaroteneThe serum concentration of Quinidine can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Quinidine is combined with Bezitramide.
BifonazoleThe metabolism of Quinidine can be decreased when combined with Bifonazole.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Quinidine.
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Quinidine.
BoceprevirThe serum concentration of Quinidine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Quinidine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Quinidine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Quinidine.
Botulinum Toxin Type AQuinidine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BQuinidine may increase the anticholinergic activities of Botulinum Toxin Type B.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Quinidine.
BrinzolamideBrinzolamide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Quinidine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Quinidine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Quinidine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Quinidine.
BuprenorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Buprenorphine.
BuprenorphineThe serum concentration of Quinidine can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Quinidine.
BuserelinBuserelin may increase the QTc-prolonging activities of Quinidine.
BuspironeThe serum concentration of Quinidine can be increased when it is combined with Buspirone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Quinidine.
ButenafineThe metabolism of Quinidine can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Quinidine can be decreased when combined with Butoconazole.
ButorphanolThe risk or severity of adverse effects can be increased when Quinidine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Quinidine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Quinidine.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Quinidine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Quinidine.
CandesartanThe serum concentration of Quinidine can be increased when it is combined with Candesartan.
CandicidinThe metabolism of Quinidine can be decreased when combined with Candicidin.
CapecitabineThe metabolism of Quinidine can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Quinidine can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Quinidine.
CarbamazepineThe serum concentration of Quinidine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Quinidine.
CarfentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Quinidine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Quinidine.
CarteololThe metabolism of Carteolol can be decreased when combined with Quinidine.
CarvedilolThe serum concentration of Quinidine can be increased when it is combined with Carvedilol.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Quinidine.
CaspofunginThe metabolism of Quinidine can be decreased when combined with Caspofungin.
CelecoxibThe metabolism of Quinidine can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Quinidine.
CeritinibCeritinib may increase the QTc-prolonging activities of Quinidine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Quinidine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Quinidine.
CeruleninThe metabolism of Quinidine can be decreased when combined with Cerulenin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Quinidine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Quinidine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Quinidine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Quinidine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Quinidine.
ChloroxineThe metabolism of Quinidine can be decreased when combined with Chloroxine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Quinidine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Quinidine is combined with Chlorphenoxamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinidine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Quinidine.
ChlorpropamideThe serum concentration of Quinidine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Quinidine can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Quinidine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Quinidine.
CholecalciferolThe metabolism of Quinidine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Quinidine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Quinidine can be decreased when it is combined with Cholic Acid.
CiclopiroxThe metabolism of Quinidine can be decreased when combined with Ciclopirox.
CilazaprilThe serum concentration of Quinidine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Quinidine.
CimetidineThe serum concentration of Quinidine can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Quinidine.
CimetropiumQuinidine may increase the anticholinergic activities of Cimetropium.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Quinidine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Quinidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Quinidine.
CisaprideCisapride may increase the QTc-prolonging activities of Quinidine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Quinidine.
CitalopramCitalopram may increase the QTc-prolonging activities of Quinidine.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Quinidine.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Quinidine.
ClemastineThe metabolism of Quinidine can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Quinidine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Quinidine.
ClofazimineThe serum concentration of Quinidine can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Quinidine.
ClomipramineThe serum concentration of Quinidine can be increased when it is combined with Clomipramine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Quinidine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Quinidine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Quinidine.
ClopidogrelThe metabolism of Quinidine can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Quinidine can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Quinidine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Quinidine.
CobicistatThe serum concentration of Quinidine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Quinidine.
CodeineThe risk or severity of adverse effects can be increased when Quinidine is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Quinidine.
ColforsinThe serum concentration of Quinidine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Quinidine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Quinidine.
CoumaphosThe therapeutic efficacy of Quinidine can be decreased when used in combination with Coumaphos.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Quinidine.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Quinidine.
CyclobenzaprineCyclobenzaprine may increase the QTc-prolonging activities of Quinidine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinidine.
CyclopentolateThe risk or severity of adverse effects can be increased when Quinidine is combined with Cyclopentolate.
CyclophosphamideThe serum concentration of Quinidine can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Quinidine.
CyclosporineThe metabolism of Quinidine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Quinidine.
Cyproterone acetateThe serum concentration of Quinidine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.
DabrafenibThe serum concentration of Quinidine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Quinidine.
DaclatasvirThe serum concentration of Quinidine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Quinidine.
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Quinidine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Quinidine.
DapsoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Dapsone.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Quinidine.
DarunavirThe serum concentration of Quinidine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Quinidine.
DasatinibThe serum concentration of Quinidine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Quinidine can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Quinidine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Quinidine.
DecamethoniumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Decamethonium.
Decanoic AcidThe metabolism of Quinidine can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Quinidine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Quinidine.
DelavirdineThe metabolism of Quinidine can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Demecarium.
DesfluraneDesflurane may increase the QTc-prolonging activities of Quinidine.
DesipramineThe serum concentration of Quinidine can be increased when it is combined with Desipramine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Quinidine.
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Quinidine.
DesloratadineThe risk or severity of adverse effects can be increased when Quinidine is combined with Desloratadine.
DexamethasoneThe serum concentration of Quinidine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Quinidine.
DexetimideThe risk or severity of adverse effects can be increased when Quinidine is combined with Dexetimide.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Quinidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Quinidine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Quinidine.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Quinidine.
DextromoramideThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Quinidine.
DichlorvosThe therapeutic efficacy of Quinidine can be decreased when used in combination with Dichlorvos.
DiclofenacThe serum concentration of Quinidine can be increased when it is combined with Diclofenac.
DiclofenamideDiclofenamide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
DicoumarolQuinidine may increase the anticoagulant activities of Dicoumarol.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Quinidine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinidine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Quinidine.
DigoxinThe serum concentration of Quinidine can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinidine.
DihydrocodeineQuinidine may decrease the analgesic activities of Dihydrocodeine.
DihydroergotamineThe metabolism of Quinidine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Quinidine.
DiltiazemThe serum concentration of Quinidine can be increased when it is combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Quinidine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Quinidine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Quinidine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Quinidine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Quinidine.
DisulfiramThe metabolism of Quinidine can be decreased when combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Quinidine.
DofetilideDofetilide may increase the QTc-prolonging activities of Quinidine.
DolasetronDolasetron may increase the QTc-prolonging activities of Quinidine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Quinidine.
DomperidoneQuinidine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe therapeutic efficacy of Quinidine can be decreased when used in combination with Donepezil.
DonepezilThe metabolism of Donepezil can be decreased when combined with Quinidine.
DopamineThe metabolism of Dopamine can be decreased when combined with Quinidine.
DorzolamideDorzolamide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
DosulepinDosulepin may increase the QTc-prolonging activities of Quinidine.
DoxazosinThe serum concentration of Quinidine can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Quinidine.
DoxepinThe serum concentration of Quinidine can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Quinidine.
DoxorubicinThe serum concentration of Quinidine can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Quinidine.
DoxycyclineThe metabolism of Quinidine can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Quinidine is combined with DPDPE.
DronabinolQuinidine may increase the tachycardic activities of Dronabinol.
DronabinolThe serum concentration of Quinidine can be increased when it is combined with Dronabinol.
DronedaroneQuinidine may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Quinidine.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Quinidine.
EchothiophateThe therapeutic efficacy of Quinidine can be decreased when used in combination with Echothiophate.
EconazoleThe metabolism of Quinidine can be decreased when combined with Econazole.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Quinidine.
EdrophoniumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of Quinidine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe metabolism of Quinidine can be decreased when combined with Efinaconazole.
ElbasvirThe serum concentration of Quinidine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Quinidine.
EliglustatQuinidine may increase the QTc-prolonging activities of Eliglustat.
EluxadolineQuinidine may increase the constipating activities of Eluxadoline.
EnalaprilThe serum concentration of Quinidine can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Quinidine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Quinidine.
EnzalutamideThe serum concentration of Quinidine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Quinidine.
EplerenoneThe therapeutic efficacy of Quinidine can be decreased when used in combination with Eplerenone.
ErgonovineThe serum concentration of Quinidine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Quinidine can be increased when it is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Quinidine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Quinidine.
ErythromycinErythromycin may increase the QTc-prolonging activities of Quinidine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Quinidine.
EscitalopramQuinidine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Quinidine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineEsmirtazapine may increase the QTc-prolonging activities of Quinidine.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Quinidine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Quinidine.
EstramustineThe serum concentration of Quinidine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Quinidine can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Quinidine.
EstroneThe serum concentration of Quinidine can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Quinidine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinidine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Quinidine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Ethyl biscoumacetateQuinidine may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Ethylmorphine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Quinidine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Quinidine.
EtorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Etorphine.
EtravirineThe serum concentration of Quinidine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Quinidine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Quinidine.
EzogabineEzogabine may increase the QTc-prolonging activities of Quinidine.
FamotidineFamotidine may increase the QTc-prolonging activities of Quinidine.
FelbamateFelbamate may increase the QTc-prolonging activities of Quinidine.
FelodipineThe serum concentration of Quinidine can be increased when it is combined with Felodipine.
FentanylThe risk or severity of adverse effects can be increased when Quinidine is combined with Fentanyl.
FentanylThe serum concentration of Quinidine can be increased when it is combined with Fentanyl.
FenthionThe therapeutic efficacy of Quinidine can be decreased when used in combination with Fenthion.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinidine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Quinidine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Quinidine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Quinidine.
FingolimodFingolimod may increase the arrhythmogenic activities of Quinidine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Quinidine.
FlecainideFlecainide may increase the QTc-prolonging activities of Quinidine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Quinidine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Quinidine.
FloxuridineThe metabolism of Quinidine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Quinidine can be decreased when combined with Fluconazole.
FlucytosineThe metabolism of Quinidine can be decreased when combined with Flucytosine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Quinidine.
FluorouracilThe metabolism of Quinidine can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Quinidine.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Quinidine.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Quinidine.
FlurazepamThe serum concentration of Quinidine can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinidine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Quinidine.
FluvoxamineThe serum concentration of Quinidine can be increased when it is combined with Fluvoxamine.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Quinidine.
FormoterolFormoterol may increase the QTc-prolonging activities of Quinidine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Quinidine.
FosamprenavirThe serum concentration of Quinidine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Quinidine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Quinidine.
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Quinidine.
Fusidic AcidThe serum concentration of Quinidine can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Quinidine.
GalantamineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Galantamine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Quinidine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Quinidine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Quinidine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Quinidine.
GemfibrozilThe metabolism of Quinidine can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Quinidine.
GenisteinThe serum concentration of Quinidine can be increased when it is combined with Genistein.
Ginkgo bilobaThe therapeutic efficacy of Quinidine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Quinidine is combined with Glucagon recombinant.
GlyburideThe serum concentration of Quinidine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Quinidine can be increased when it is combined with Glycerol.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Quinidine.
GlycopyrroniumQuinidine may increase the anticholinergic activities of Glycopyrronium.
GlyphosateThe metabolism of Quinidine can be decreased when combined with Glyphosate.
GoserelinGoserelin may increase the QTc-prolonging activities of Quinidine.
Gramicidin DThe serum concentration of Quinidine can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Quinidine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Quinidine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Quinidine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Quinidine.
GriseofulvinThe metabolism of Quinidine can be decreased when combined with Griseofulvin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Quinidine.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Quinidine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Quinidine.
HaloproginThe metabolism of Quinidine can be decreased when combined with Haloprogin.
HalothaneThe metabolism of Halothane can be decreased when combined with Quinidine.
HeroinThe risk or severity of adverse effects can be increased when Quinidine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Hexamethonium.
HexetidineThe metabolism of Quinidine can be decreased when combined with Hexetidine.
HistrelinHistrelin may increase the QTc-prolonging activities of Quinidine.
HomatropineThe risk or severity of adverse effects can be increased when Quinidine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Quinidine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Quinidine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Quinidine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Quinidine.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Quinidine.
HydromorphoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Quinidine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Quinidine.
IbandronateIbandronate may increase the QTc-prolonging activities of Quinidine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Quinidine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Quinidine.
IbutilideIbutilide may increase the QTc-prolonging activities of Quinidine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Quinidine.
IdelalisibThe serum concentration of Quinidine can be increased when it is combined with Idelalisib.
IloperidoneQuinidine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Quinidine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Quinidine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quinidine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Quinidine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Quinidine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Quinidine.
IndapamideIndapamide may increase the QTc-prolonging activities of Quinidine.
IndinavirThe serum concentration of Quinidine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Quinidine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Quinidine.
IrbesartanThe metabolism of Quinidine can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Quinidine.
IsavuconazoniumThe metabolism of Quinidine can be decreased when combined with Isavuconazonium.
IsoconazoleThe metabolism of Quinidine can be decreased when combined with Isoconazole.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Quinidine.
IsoflurophateThe therapeutic efficacy of Quinidine can be decreased when used in combination with Isoflurophate.
IsoniazidThe metabolism of Quinidine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Quinidine can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Quinidine.
ItraconazoleThe metabolism of Quinidine can be decreased when combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Quinidine.
IvacaftorThe serum concentration of Quinidine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Quinidine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Quinidine.
KaolinThe serum concentration of Quinidine can be decreased when it is combined with Kaolin.
KetamineThe serum concentration of Quinidine can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Quinidine.
KetobemidoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Ketobemidone.
KetoconazoleThe metabolism of Quinidine can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Quinidine.
LabetalolThe metabolism of Labetalol can be decreased when combined with Quinidine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Quinidine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Quinidine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Quinidine.
LapatinibThe serum concentration of Quinidine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Quinidine.
LeflunomideThe metabolism of Quinidine can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Quinidine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Quinidine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Quinidine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Quinidine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Quinidine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Quinidine.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Quinidine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Quinidine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Quinidine is combined with Levomethadyl Acetate.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Quinidine.
LevorphanolThe risk or severity of adverse effects can be increased when Quinidine is combined with Levorphanol.
LevothyroxineThe serum concentration of Quinidine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Quinidine can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Quinidine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Quinidine.
LiothyronineThe serum concentration of Quinidine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Quinidine can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Quinidine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Quinidine.
LithiumLithium may increase the QTc-prolonging activities of Quinidine.
LofentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Lofentanil.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Quinidine.
LomustineThe metabolism of Lomustine can be decreased when combined with Quinidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Quinidine.
LopinavirLopinavir may increase the QTc-prolonging activities of Quinidine.
LoratadineThe serum concentration of Quinidine can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Quinidine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Quinidine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Quinidine.
LovastatinThe metabolism of Quinidine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Quinidine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Quinidine can be decreased when it is combined with Lumacaftor.
LumefantrineThe risk or severity of adverse effects can be increased when Quinidine is combined with Lumefantrine.
LumefantrineLumefantrine may increase the QTc-prolonging activities of Quinidine.
LurasidoneLurasidone may increase the QTc-prolonging activities of Quinidine.
MagaldrateMagaldrate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
MalathionThe therapeutic efficacy of Quinidine can be decreased when used in combination with Malathion.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Quinidine.
MaprotilineThe serum concentration of Quinidine can be increased when it is combined with Maprotiline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Quinidine.
MebendazoleThe serum concentration of Quinidine can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinidine.
MefloquineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mefloquine.
MefloquineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Mefloquine.
Megestrol acetateThe serum concentration of Quinidine can be increased when it is combined with Megestrol acetate.
MemantineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Memantine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Quinidine.
MeprobamateThe serum concentration of Quinidine can be increased when it is combined with Meprobamate.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Quinidine.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Quinidine.
MethadoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Methadone.
MethadoneMethadone may increase the QTc-prolonging activities of Quinidine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Quinidine is combined with Methadyl Acetate.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Quinidine.
MethanthelineThe risk or severity of adverse effects can be increased when Quinidine is combined with Methantheline.
MethazolamideMethazolamide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Quinidine.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinidine.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Quinidine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Quinidine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Quinidine.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Quinidine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Quinidine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Quinidine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Quinidine.
MetixeneThe risk or severity of adverse effects can be increased when Quinidine is combined with Metixene.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Quinidine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Quinidine.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Quinidine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Quinidine.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Quinidine.
MevastatinThe metabolism of Quinidine can be decreased when combined with Mevastatin.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Quinidine.
MianserinMianserin may increase the anticholinergic activities of Quinidine.
MianserinThe metabolism of Mianserin can be decreased when combined with Quinidine.
MibefradilThe serum concentration of Quinidine can be increased when it is combined with Mibefradil.
MicafunginThe metabolism of Quinidine can be decreased when combined with Micafungin.
MiconazoleThe metabolism of Quinidine can be decreased when combined with Miconazole.
MidazolamThe serum concentration of Quinidine can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quinidine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Quinidine.
MiltefosineThe metabolism of Quinidine can be decreased when combined with Miltefosine.
MinaprineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Minaprine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Quinidine.
MirabegronThe risk or severity of adverse effects can be increased when Quinidine is combined with Mirabegron.
MirabegronMirabegron may increase the QTc-prolonging activities of Quinidine.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Quinidine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Quinidine.
MitomycinThe serum concentration of Quinidine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Quinidine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Quinidine can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Quinidine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Quinidine.
ModafinilThe serum concentration of Quinidine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Quinidine.
MonensinThe metabolism of Quinidine can be decreased when combined with Monensin.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Quinidine.
MorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Morphine.
MorphineThe serum concentration of Quinidine can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Quinidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinidine.
MyxothiazolThe metabolism of Quinidine can be decreased when combined with Myxothiazol.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Quinidine is combined with N-butylscopolammonium bromide.
NabiloneQuinidine may increase the tachycardic activities of Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Quinidine.
NafcillinThe serum concentration of Quinidine can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Quinidine can be decreased when combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Quinidine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Quinidine.
NaltrexoneThe serum concentration of Quinidine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Quinidine can be increased when it is combined with Naringenin.
NatamycinThe metabolism of Quinidine can be decreased when combined with Natamycin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Quinidine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Quinidine.
NefazodoneThe serum concentration of Quinidine can be decreased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Quinidine.
NelfinavirThe serum concentration of Quinidine can be increased when it is combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Quinidine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Quinidine.
NevirapineThe metabolism of Quinidine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Quinidine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Quinidine.
NicotineThe metabolism of Nicotine can be decreased when combined with Quinidine.
NifedipineThe serum concentration of Quinidine can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Quinidine.
NilotinibQuinidine may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Quinidine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Quinidine.
NisoldipineThe serum concentration of Quinidine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Quinidine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Quinidine can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Quinidine.
NitroxolineThe metabolism of Quinidine can be decreased when combined with Nitroxoline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Quinidine.
NorethisteroneThe serum concentration of Quinidine can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Quinidine.
NormethadoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Normethadone.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Quinidine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Quinidine.
NVA237The risk or severity of adverse effects can be increased when Quinidine is combined with NVA237.
NystatinThe metabolism of Quinidine can be decreased when combined with Nystatin.
OctreotideOctreotide may increase the QTc-prolonging activities of Quinidine.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Quinidine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Quinidine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Quinidine.
OlaparibThe metabolism of Quinidine can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Quinidine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Quinidine.
OmeprazoleThe serum concentration of Quinidine can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Quinidine.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Quinidine.
OpiumThe risk or severity of adverse effects can be increased when Quinidine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Quinidine is combined with Orphenadrine.
OsimertinibThe serum concentration of Quinidine can be increased when it is combined with Osimertinib.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Quinidine.
OxiconazoleThe metabolism of Quinidine can be decreased when combined with Oxiconazole.
OxybutyninThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Quinidine.
OxytocinOxytocin may increase the QTc-prolonging activities of Quinidine.
P-NitrophenolThe serum concentration of Quinidine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Quinidine.
pafuramidineThe metabolism of Quinidine can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Quinidine can be increased when it is combined with Palbociclib.
PaliperidoneQuinidine may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Quinidine can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Quinidine.
PancuroniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Pancuronium.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Quinidine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Quinidine.
PantoprazoleThe serum concentration of Quinidine can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Quinidine can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Quinidine.
PasireotidePasireotide may increase the QTc-prolonging activities of Quinidine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Quinidine.
PazopanibPazopanib may increase the QTc-prolonging activities of Quinidine.
PentamidineThe metabolism of Quinidine can be decreased when combined with Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine.
PentobarbitalThe metabolism of Quinidine can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentolinium.
PerflutrenPerflutren may increase the QTc-prolonging activities of Quinidine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Quinidine.
PerindoprilThe serum concentration of Quinidine can be increased when it is combined with Perindopril.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Quinidine.
PethidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Quinidine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Quinidine.
PhenindioneQuinidine may increase the anticoagulant activities of Phenindione.
PhenobarbitalPhenobarbital may increase the hepatotoxic activities of Quinidine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Quinidine.
PhenprocoumonQuinidine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Quinidine can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Quinidine.
PhysostigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Physostigmine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Quinidine.
PimozidePimozide may increase the QTc-prolonging activities of Quinidine.
PindololThe metabolism of Pindolol can be decreased when combined with Quinidine.
PioglitazoneThe metabolism of Quinidine can be decreased when combined with Pioglitazone.
PipecuroniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Pipecuronium.
PiperazineThe metabolism of Piperazine can be decreased when combined with Quinidine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Quinidine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Quinidine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Quinidine.
Platelet Activating FactorThe serum concentration of Quinidine can be decreased when it is combined with Platelet Activating Factor.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Quinidine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Quinidine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Quinidine.
PosaconazoleThe metabolism of Quinidine can be decreased when combined with Posaconazole.
Potassium ChlorideQuinidine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Quinidine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Quinidine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Quinidine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Quinidine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Quinidine.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Quinidine.
PrimidoneThe serum concentration of Quinidine can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Quinidine can be increased when it is combined with Probenecid.
ProcainamideQuinidine may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinidine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Quinidine.
ProgesteroneThe serum concentration of Quinidine can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Quinidine.
PromazineThe serum concentration of Promazine can be increased when it is combined with Quinidine.
PromazinePromazine may increase the QTc-prolonging activities of Quinidine.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Quinidine.
PropafenonePropafenone may increase the arrhythmogenic activities of Quinidine.
PropafenoneQuinidine may increase the QTc-prolonging activities of Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Quinidine.
PropofolPropofol may increase the QTc-prolonging activities of Quinidine.
PropofolThe metabolism of Propofol can be decreased when combined with Quinidine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Quinidine.
ProtriptylineThe serum concentration of Quinidine can be increased when it is combined with Protriptyline.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Quinidine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Quinidine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Quinidine.
PyridostigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Pyridostigmine.
PyrimethamineThe metabolism of Quinidine can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Quinidine can be increased when it is combined with Quercetin.
QuetiapineQuinidine may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Quinidine can be increased when it is combined with Quinacrine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Quinidine.
QuinineQuinine may increase the QTc-prolonging activities of Quinidine.
RabeprazoleThe metabolism of Quinidine can be decreased when combined with Rabeprazole.
RadicicolThe metabolism of Quinidine can be decreased when combined with Radicicol.
RamosetronQuinidine may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Quinidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Quinidine.
ReboxetineThe serum concentration of Quinidine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Quinidine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Remifentanil.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Quinidine.
repinotanThe metabolism of repinotan can be decreased when combined with Quinidine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinidine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Quinidine.
RifabutinThe metabolism of Quinidine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Quinidine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Quinidine.
RifapentineThe metabolism of Quinidine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Quinidine.
RilpivirineThe serum concentration of Quinidine can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Quinidine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Quinidine.
RitonavirThe serum concentration of Quinidine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Quinidine.
RivastigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Rivastigmine.
RolapitantThe serum concentration of Quinidine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Quinidine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Quinidine.
RosiglitazoneThe metabolism of Quinidine can be decreased when combined with Rosiglitazone.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Quinidine.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Quinidine.
Salicylhydroxamic AcidThe metabolism of Quinidine can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidThe metabolism of Quinidine can be decreased when combined with Salicylic acid.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Quinidine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Quinidine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Quinidine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Quinidine.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Quinidine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Quinidine is combined with Scopolamine butylbromide.
SecobarbitalThe metabolism of Quinidine can be increased when combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Quinidine.
SelegilineThe serum concentration of Quinidine can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Quinidine.
SertaconazoleThe metabolism of Quinidine can be decreased when combined with Sertaconazole.
SertindoleThe metabolism of Sertindole can be decreased when combined with Quinidine.
SertralineThe serum concentration of Quinidine can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Quinidine.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Quinidine.
SildenafilThe metabolism of Quinidine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Quinidine.
SiltuximabThe serum concentration of Quinidine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Quinidine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Quinidine can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Quinidine.
SinefunginThe metabolism of Quinidine can be decreased when combined with Sinefungin.
SirolimusThe metabolism of Quinidine can be decreased when combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Quinidine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Quinidine.
SolifenacinThe risk or severity of adverse effects can be increased when Quinidine is combined with Solifenacin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Quinidine.
SotalolSotalol may increase the QTc-prolonging activities of Quinidine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Quinidine.
SparteineThe metabolism of Sparteine can be decreased when combined with Quinidine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Quinidine.
SpironolactoneThe therapeutic efficacy of Quinidine can be decreased when used in combination with Spironolactone.
St. John's WortThe serum concentration of Quinidine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Quinidine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Quinidine can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Quinidine can be decreased when it is combined with Streptozocin.
SucralfateThe serum concentration of Quinidine can be decreased when it is combined with Sucralfate.
SufentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.
SulconazoleThe metabolism of Quinidine can be decreased when combined with Sulconazole.
SulfadiazineThe metabolism of Quinidine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Quinidine can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Quinidine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Quinidine.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinidine.
SumatriptanThe serum concentration of Quinidine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Quinidine can be increased when it is combined with Sunitinib.
TacrineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Tacrine.
TacrolimusThe serum concentration of Quinidine can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Quinidine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Quinidine resulting in a loss in efficacy.
TamoxifenThe serum concentration of Quinidine can be decreased when it is combined with Tamoxifen.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Quinidine.
TapentadolThe risk or severity of adverse effects can be increased when Quinidine is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Quinidine.
TavaboroleThe metabolism of Quinidine can be decreased when combined with Tavaborole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Quinidine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Quinidine.
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Quinidine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Quinidine.
TelavancinTelavancin may increase the QTc-prolonging activities of Quinidine.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Quinidine.
TelmisartanThe serum concentration of Quinidine can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Quinidine.
TerazosinThe serum concentration of Quinidine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Quinidine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Quinidine.
TerconazoleThe metabolism of Quinidine can be decreased when combined with Terconazole.
TerfenadineThe serum concentration of Quinidine can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Quinidine.
TeriflunomideThe metabolism of Quinidine can be decreased when combined with Teriflunomide.
TesmilifeneThe serum concentration of Quinidine can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Quinidine.
TestosteroneThe serum concentration of Quinidine can be increased when it is combined with Testosterone.
TetrabenazineQuinidine may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Quinidine.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Quinidine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quinidine.
ThioridazineThioridazine may increase the QTc-prolonging activities of Quinidine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Quinidine.
ThymolThe metabolism of Quinidine can be decreased when combined with Thymol.
TianeptineTianeptine may increase the QTc-prolonging activities of Quinidine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Quinidine.
TiclopidineThe metabolism of Quinidine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Quinidine.
TioconazoleThe metabolism of Quinidine can be decreased when combined with Tioconazole.
TiotropiumQuinidine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Quinidine.
TipranavirThe serum concentration of Quinidine can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Quinidine.
TizanidineTizanidine may increase the QTc-prolonging activities of Quinidine.
TocilizumabThe serum concentration of Quinidine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Quinidine can be decreased when combined with Tolbutamide.
TolnaftateThe metabolism of Quinidine can be decreased when combined with Tolnaftate.
TolterodineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tolterodine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Quinidine.
TopiramateThe risk or severity of adverse effects can be increased when Quinidine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Quinidine.
ToremifeneToremifene may increase the QTc-prolonging activities of Quinidine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Quinidine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinidine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Quinidine.
TrazodoneThe serum concentration of Quinidine can be decreased when it is combined with Trazodone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Quinidine.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Quinidine.
TriamtereneThe therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.
TrichlorfonThe therapeutic efficacy of Quinidine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Quinidine.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinidine.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Quinidine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Quinidine.
TrimethaphanThe risk or severity of adverse effects can be increased when Quinidine is combined with Trimethaphan.
TrimethoprimThe serum concentration of Quinidine can be decreased when it is combined with Trimethoprim.
TrimetrexateThe metabolism of Quinidine can be decreased when combined with Trimetrexate.
TrimipramineThe serum concentration of Quinidine can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Quinidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Quinidine.
TroleandomycinThe serum concentration of Quinidine can be increased when it is combined with Troleandomycin.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Quinidine.
TubocurarineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tubocurarine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Quinidine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Quinidine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Umeclidinium.
Valproic AcidThe metabolism of Quinidine can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Quinidine can be decreased when combined with Valsartan.
VandetanibQuinidine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Quinidine.
VecuroniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Vecuronium.
VemurafenibQuinidine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Quinidine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Quinidine.
VerapamilQuinidine may increase the hypotensive activities of Verapamil.
VerapamilThe metabolism of Quinidine can be decreased when combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Quinidine.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Quinidine.
VinblastineThe serum concentration of Quinidine can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Quinidine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Quinidine.
VincristineThe serum concentration of Quinidine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Quinidine can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Quinidine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Quinidine.
VoriconazoleThe metabolism of Quinidine can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Quinidine.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Quinidine.
WarfarinQuinidine may increase the anticoagulant activities of Warfarin.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Quinidine.
ZafirlukastThe metabolism of Quinidine can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Quinidine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Quinidine.
ZimelidineThe serum concentration of Quinidine can be increased when it is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Quinidine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Quinidine.
ZuclopenthixolQuinidine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Preferably take on an ampty stomach.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA, Huang CL: Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3. J Physiol. 2007 Jan 1;578(Pt 1):69-84. Epub 2006 Oct 5. [PubMed:17023504 ]
  2. Itoh H, Shimizu M, Takata S, Mabuchi H, Imoto K: A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol. 2005 May;16(5):486-93. [PubMed:15877619 ]
  3. Grant AO: Electrophysiological basis and genetics of Brugada syndrome. J Cardiovasc Electrophysiol. 2005 Sep;16 Suppl 1:S3-7. [PubMed:16138883 ]
  4. Napolitano C, Priori SG: Brugada syndrome. Orphanet J Rare Dis. 2006 Sep 14;1:35. [PubMed:16972995 ]
  5. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Ohe T, Shimizu W: Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007 Jun;4(6):695-700. Epub 2007 Feb 20. [PubMed:17556186 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med. 2010 Jan;20(1):16-21. doi: 10.1016/j.tcm.2010.03.002. [PubMed:20685573 ]
  8. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium channel activity
Specific Function:
Ion channel that contributes to passive transmembrane potassium transport and to the regulation of the resting membrane potential in brain astrocytes, but also in kidney and in other tissues (PubMed:15820677, PubMed:21653227). Forms dimeric channels through which potassium ions pass in accordance with their electrochemical gradient. The channel is selective for K(+) ions at physiological potass...
Gene Name:
KCNK1
Uniprot ID:
O00180
Molecular Weight:
38142.775 Da
References
  1. Lesage F, Guillemare E, Fink M, Duprat F, Lazdunski M, Romey G, Barhanin J: TWIK-1, a ubiquitous human weakly inward rectifying K+ channel with a novel structure. EMBO J. 1996 Mar 1;15(5):1004-11. [PubMed:8605869 ]
  2. Fink M, Duprat F, Lesage F, Reyes R, Romey G, Heurteaux C, Lazdunski M: Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel. EMBO J. 1996 Dec 16;15(24):6854-62. [PubMed:9003761 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Potassium ion leak channel activity
Specific Function:
Exhibits outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical K(+) conditions.
Gene Name:
KCNK6
Uniprot ID:
Q9Y257
Molecular Weight:
33746.8 Da
References
  1. Patel AJ, Maingret F, Magnone V, Fosset M, Lazdunski M, Honore E: TWIK-2, an inactivating 2P domain K+ channel. J Biol Chem. 2000 Sep 15;275(37):28722-30. [PubMed:10887187 ]
  2. Guerard NC, Traebert M, Suter W, Dumotier BM: Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):32-40. doi: 10.1016/j.vascn.2008.05.129. Epub 2008 Jun 8. [PubMed:18582585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Po SS, Wang DW, Yang IC, Johnson JP Jr, Nie L, Bennett PB: Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol. 1999 Feb;33(2):181-5. [PubMed:10028924 ]
  2. Dong DL, Li Z, Wang HZ, Du ZM, Song WH, Yang BF: Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. Basic Clin Pharmacol Toxicol. 2004 May;94(5):209-12. [PubMed:15125690 ]
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. [PubMed:15673388 ]
  4. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J: The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther. 2005 Mar;10(1):67-76. [PubMed:15821840 ]
  5. Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J: A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther. 2005 Jul-Aug;12(4):328-36. [PubMed:16041196 ]
  6. Guerard NC, Traebert M, Suter W, Dumotier BM: Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):32-40. doi: 10.1016/j.vascn.2008.05.129. Epub 2008 Jun 8. [PubMed:18582585 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. van Montfoort JE, Hagenbuch B, Fattinger KE, Muller M, Groothuis GM, Meijer DK, Meier PJ: Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52. [PubMed:10490898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Li JH, Xu JQ, Cao XM, Ni L, Li Y, Zhuang YY, Gong JB: Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin Chim Acta. 2002 Mar;317(1-2):85-92. [PubMed:11814462 ]
  2. McCollam PL, Crouch MA, Arnaud P: Caucasian versus African-American differences in orosomucoid: potential implications for therapy. Pharmacotherapy. 1998 May-Jun;18(3):620-6. [PubMed:9620113 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595 ]
  3. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ: Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5. [PubMed:11408531 ]
  2. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
  3. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  4. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  5. Zhang L, Gorset W, Dresser MJ, Giacomini KM: The interaction of n-tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J Pharmacol Exp Ther. 1999 Mar;288(3):1192-8. [PubMed:10027858 ]
  6. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
  7. Sinclair CJ, Chi KD, Subramanian V, Ward KL, Green RM: Functional expression of a high affinity mammalian hepatic choline/organic cation transporter. J Lipid Res. 2000 Nov;41(11):1841-8. [PubMed:11060354 ]
  8. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595 ]
  9. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712 ]
  10. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, Schomig E: Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):320-6. [PubMed:8878062 ]
  11. Busch AE, Quester S, Ulzheimer JC, Gorboulev V, Akhoundova A, Waldegger S, Lang F, Koepsell H: Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1. FEBS Lett. 1996 Oct 21;395(2-3):153-6. [PubMed:8898084 ]
  12. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [PubMed:8955087 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  2. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  4. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  5. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  6. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  7. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
  8. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5. [PubMed:1359120 ]
  9. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
  10. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94. [PubMed:9435299 ]
  11. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  12. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272 ]
  13. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
  14. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  15. Smith BJ, Doran AC, McLean S, Tingley FD 3rd, O'Neill BT, Kajiji SM: P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9. [PubMed:11504828 ]
  16. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  17. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010 ]
  18. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  19. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
  20. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999 Feb 2;99(4):552-7. [PubMed:9927403 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ: Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5. [PubMed:11408531 ]
  2. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
  3. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
  4. van Montfoort JE, Hagenbuch B, Fattinger KE, Muller M, Groothuis GM, Meijer DK, Meier PJ: Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52. [PubMed:10490898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:26